Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Real-time Estimate Cboe Europe  -  09:52 2022-09-26 am EDT
84.35 CHF   +0.90%
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution
EQ
09/09TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : 2022 Half-Year Unaudited Top-Line Figures Presentation

07/29/2022 | 01:14am EDT

1H 2022 Preliminary Unaudited Top-Line Figures

29 July 2022

Disclaimer

This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at https://www.medacta.com/EN/investors.

Unaudited Financial Results

The financial information contained in this Presentation is unaudited.

Forward-looking information

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates", "targets", "plans", "outlook" or similar expressions.

There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The COVID-19 outbreak has caused, and may continue to cause, economic instability and a significant decrease of total economic output in the affected areas and globally. The impact of the COVID-19 outbreak on the general economic environment in the markets in which Medacta operates remain uncertain and could be significant. In addition, other important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

Alternative Performance Measures

This Presentation may contain information regarding alternative performance measures. Definitions of these measures and reconciliations between such measures and their IFRS counterparts if not defined in the Presentation may be found on the financial reports available on our website at https://www.medacta.com/EN/investors.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP.

2

FRANCESCO SICCARDI

CORRADO FARSETTA

Chief Executive Officer

Chief Financial Officer

1H 2022 Preliminary Unaudited Top-Line Figures

1H 2022 Highlights

  • 1H 2022 revenue increased to Euro 211.3 million, or 19.0% (14.6% at constant currency) from 1H 2021
  • Significant customer acquisition, salesforce expansion and product introduction drove the growth that was limited by pandemic restrictions and hospital staffing shortages in Australia and US
  • Compared to 1H 2019, revenue was up 36.5% at constant currency, representing a CAGR of 10.9% c.c., true growth beyond a mere recovery
  • Milestone of 100 NextAR™ platforms in the market, driven by the full market release of NextAR™ shoulder application
  • Further expansion of our network of expert surgeons with 500+ reference centers active worldwide to support our Marketing and Medical Education Programs
  • The expansion of our salesforce continued across all the geographies and business lines

4

1H 2022 Revenue1 Bridge by Product Line

11.1%

16.1%

35.6%

16.0%

14.6%

19.0%

19.8; 9%

(€m, %)

12.9;

(€m)

6%

101.4;

77.2;

48%

37%

2

Hip Knee Extremities Spine

  • Hip: growth driven by the AMIS® strategy, supported by further adoption of the Bikini technique, and the roll-out of new products
  • Knee: good momentum generated by Kinematic Alignment, Efficiency single-use instruments and the GMK® Sphere implants
  • Extremities: acquisition of new customers through the completeness of the Medacta Shoulder System, supported by MyShoulder® and NextAR™ personalized solutions
  • Spine: growth driven by MIS Platform expansion and MySpine® offering

Notes:

1.

Unaudited

2.

Extremities include Shoulder and Sports Med revenue

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Medacta Group SA published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2022 05:13:09 UTC.


© Publicnow 2022
All news about MEDACTA GROUP SA
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
09/09TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
09/09Swiss Orthopedic Group Medacta Lifts FY22 Outlook as H1 Revenue Grows; Profit Slows
MT
09/09MEDACTA : 2022 Half-Year Report
PU
09/09MEDACTA : 2022 Half-Year Presentation
PU
09/09Medacta Group SA reports strong revenue growth of 19.0% and adjusted EBITDA margin of 2..
EQ
09/09Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022
CI
09/08Medacta Group SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 428 M 416 M 416 M
Net income 2022 55,8 M 54,3 M 54,3 M
Net Debt 2022 137 M 134 M 134 M
P/E ratio 2022 30,7x
Yield 2022 0,71%
Capitalization 1 751 M 1 703 M 1 703 M
EV / Sales 2022 4,41x
EV / Sales 2023 3,81x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 87,66 €
Average target price 110,94 €
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-41.13%1 703
ABBOTT LABORATORIES-28.46%176 313
MEDTRONIC PLC-20.10%109 868
BECTON, DICKINSON AND COMPANY-4.82%66 713
HOYA CORPORATION-17.56%35 356
DEXCOM, INC.-39.91%31 666